Tags

Type your tag names separated by a space and hit enter

Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study).
J Hypertens. 2012 Dec; 30(12):2357-64.JH

Abstract

OBJECTIVE

Optimal blood pressure (BP) control in acute intracerebral hemorrhage (ICH) remains controversial. We determined the effects of SBP lowering to 160 mmHg or more using intravenous nicardipine for acute ICH patients.

METHODS

This is a prospective, multicenter, observational study conducted in Japan, with the lack of control groups. Patients with supratentorial ICH within 3 h of onset, admission SBP 180 mmHg or more, Glasgow Coma Scale (GCS) 5 or more, and hematoma volume less than 60 ml were initially treated with intravenous nicardipine to maintain SBP between 120 and 160 mmHg with 24-h frequent BP monitoring. The primary endpoints were neurological deterioration within 72 h [GCS decrement ≥ 2 points or National Institutes of Health Stroke Scale (NIHSS) increment ≥ 4 points; estimated 90% confidence interval (CI) on the basis of previous studies: 15.2-25.9%] and serious adverse effects (SAE) to stopping intravenous nicardipine within 24 h (1.8-8.9%). The secondary endpoints included hematoma expansion more than 33% at 24 h (17.1-28.3%), modified Rankin Scale (mRS) 4 or more (54.5-67.9%) and death at 3 months (6.0-13.5%).

RESULTS

We enrolled 211 Japanese patients (81 women, 65.6 ± 12.0 years old). At baseline, BP was 201.8 ± 15.7/107.9 ± 15.0 mmHg. Median hematoma volume was 10.2 ml (interquartile range 5.6-19.2), and NIHSS score was 13 (8-17). Neurological deterioration was identified in 17 patients (8.1%), SAE in two (0.9%), hematoma expansion in 36 (17.1%), mRS 4 or more in 87 (41.2%), and death in four (1.9%). All the results were equal to or below the estimated lower 90% CI.

CONCLUSION

SBP lowering to 160 mmHg or less using nicardipine appears to be well tolerated and feasible for acute ICH.

Authors+Show Affiliations

Division of Stroke Care Unit, National Cerebral and Cardiovascular Center, Suita, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22990355

Citation

Koga, Masatoshi, et al. "Systolic Blood Pressure Lowering to 160 mmHg or Less Using Nicardipine in Acute Intracerebral Hemorrhage: a Prospective, Multicenter, Observational Study (the Stroke Acute Management With Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage Study)." Journal of Hypertension, vol. 30, no. 12, 2012, pp. 2357-64.
Koga M, Toyoda K, Yamagami H, et al. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). J Hypertens. 2012;30(12):2357-64.
Koga, M., Toyoda, K., Yamagami, H., Okuda, S., Okada, Y., Kimura, K., Shiokawa, Y., Nakagawara, J., Furui, E., Hasegawa, Y., Kario, K., Osaki, M., Miyagi, T., Endo, K., Nagatsuka, K., & Minematsu, K. (2012). Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). Journal of Hypertension, 30(12), 2357-64. https://doi.org/10.1097/HJH.0b013e328359311b
Koga M, et al. Systolic Blood Pressure Lowering to 160 mmHg or Less Using Nicardipine in Acute Intracerebral Hemorrhage: a Prospective, Multicenter, Observational Study (the Stroke Acute Management With Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage Study). J Hypertens. 2012;30(12):2357-64. PubMed PMID: 22990355.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). AU - Koga,Masatoshi, AU - Toyoda,Kazunori, AU - Yamagami,Hiroshi, AU - Okuda,Satoshi, AU - Okada,Yasushi, AU - Kimura,Kazumi, AU - Shiokawa,Yoshiaki, AU - Nakagawara,Jyoji, AU - Furui,Eisuke, AU - Hasegawa,Yasuhiro, AU - Kario,Kazuomi, AU - Osaki,Masato, AU - Miyagi,Tetsuya, AU - Endo,Kaoru, AU - Nagatsuka,Kazuyuki, AU - Minematsu,Kazuo, AU - ,, PY - 2012/9/20/entrez PY - 2012/9/20/pubmed PY - 2013/7/3/medline SP - 2357 EP - 64 JF - Journal of hypertension JO - J Hypertens VL - 30 IS - 12 N2 - OBJECTIVE: Optimal blood pressure (BP) control in acute intracerebral hemorrhage (ICH) remains controversial. We determined the effects of SBP lowering to 160 mmHg or more using intravenous nicardipine for acute ICH patients. METHODS: This is a prospective, multicenter, observational study conducted in Japan, with the lack of control groups. Patients with supratentorial ICH within 3 h of onset, admission SBP 180 mmHg or more, Glasgow Coma Scale (GCS) 5 or more, and hematoma volume less than 60 ml were initially treated with intravenous nicardipine to maintain SBP between 120 and 160 mmHg with 24-h frequent BP monitoring. The primary endpoints were neurological deterioration within 72 h [GCS decrement ≥ 2 points or National Institutes of Health Stroke Scale (NIHSS) increment ≥ 4 points; estimated 90% confidence interval (CI) on the basis of previous studies: 15.2-25.9%] and serious adverse effects (SAE) to stopping intravenous nicardipine within 24 h (1.8-8.9%). The secondary endpoints included hematoma expansion more than 33% at 24 h (17.1-28.3%), modified Rankin Scale (mRS) 4 or more (54.5-67.9%) and death at 3 months (6.0-13.5%). RESULTS: We enrolled 211 Japanese patients (81 women, 65.6 ± 12.0 years old). At baseline, BP was 201.8 ± 15.7/107.9 ± 15.0 mmHg. Median hematoma volume was 10.2 ml (interquartile range 5.6-19.2), and NIHSS score was 13 (8-17). Neurological deterioration was identified in 17 patients (8.1%), SAE in two (0.9%), hematoma expansion in 36 (17.1%), mRS 4 or more in 87 (41.2%), and death in four (1.9%). All the results were equal to or below the estimated lower 90% CI. CONCLUSION: SBP lowering to 160 mmHg or less using nicardipine appears to be well tolerated and feasible for acute ICH. SN - 1473-5598 UR - https://www.unboundmedicine.com/medline/citation/22990355/Systolic_blood_pressure_lowering_to_160_mmHg_or_less_using_nicardipine_in_acute_intracerebral_hemorrhage:_a_prospective_multicenter_observational_study__the_Stroke_Acute_Management_with_Urgent_Risk_factor_Assessment_and_Improvement_Intracerebral_Hemorrhage_study__ L2 - https://doi.org/10.1097/HJH.0b013e328359311b DB - PRIME DP - Unbound Medicine ER -